This study aims to assess the cost drivers of five blood cancers: acute leukemia, chronic leukemia, lymphoma, multiple myeloma, and bone marrow disorders.
It examines both the total healthcare allowed spending and the patient out-of-pocket costs from the year prior to diagnosis with a blood cancer through the three years after. This study offers metrics on the cost of blood cancer care to inform payers, providers, patients, patient advocates, and policymakers.
This report was commissioned by The Leukemia & Lymphoma Society (LLS), which received support for this work from Pfizer, Inc., Genentech, Inc., and Amgen, Inc. Inc..